Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 6, 2011, Pages 859-870

  Arya, Geetanjali ^a   Vandana, Mallaredy ^a   Acharya, Sarbari ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Chitosan nanoparticles; Gemcitabine; Herceptin; Pancreatic cancer; Targeted drug delivery

Indexed keywords

CHITOSAN NANOPARTICLES; GEMCITABINE; HERCEPTIN; PANCREATIC CANCERS; TARGETED DRUG DELIVERY;

CELL DEATH; CHITOSAN; DISEASES; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; ONCOLOGY;

DRUG PRODUCTS;

CHITOSAN; GEMCITABINE; NANOPARTICLE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG POTENTIATION; DRUG RELEASE; DRUG RETENTION; DRUG TARGETING; HUMAN; HUMAN CELL; PANCREAS CANCER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHITOSAN; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; HEK293 CELLS; HUMANS; NANOPARTICLES; PANCREAS; PANCREATIC NEOPLASMS;

EID: 81155146636     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.03.009     Document Type: Article

References (41)

1. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
2. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997, 15:2403-2413.
3. Huang P., Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995, 36:181-188.
4. Pasut G., Canal F., Dalla Via L., Arpicco S., Veronese F.M., Schiavon O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J Control Release 2008, 127:239-248.
5. Vandana M., Sahoo S.K. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 2010, 31:9340-9356.
6. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8:1112-1120.
7. Parveen S., Sahoo S.K. Polymeric nanoparticles for cancer therapy. J Drug Target 2008, 16:108-123.
8. Agnihotri S.A., Mallikarjuna N.N., Aminabhavi T.M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004, 100:5-28.
9. Tiyaboonchai W. Chitosan Nanoparticles: A promising system for drug delivery. Naresuan Univ J 2003, 11:51-66.
10. Das M., Mohanty C., Sahoo S.K. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 2009, 6:285-304.
11. Kimura K., Sawada T., Komatsu M., Inoue M., Muguruma K., Nishihara T., et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006, 12:4925-4932.
12. Calvo P., Remuñan-López C., Vila-Jato J.L., Alonso M.J. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997, 14:1431-1436.
13. Parveen S., Mitra M., Krishnakumar S., Sahoo S.K. Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. Acta Biomater 2010, 6:3120-3131.
14. Acharya S., Dilnawaz F., Sahoo S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009, 30:5737-5750.
15. Dilnawaz F., Singh A., Mohanty C., Sahoo S.K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010, 31:3694-3706.
16. Misra R., Acharya S., Dilnawaz F., Sahoo S.K. Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles. Nanomedicine (Lond) 2009, 4:519-530.
17. Vandana M., Sahoo S.K. Optimization of physicochemical parameters influencing the fabrication of protein-loaded chitosan nanoparticles. Nanomedicine (Lond) 2009, 4:773-785.
18. Zeng R., Tu M., Liu H.W., Zhao J.H., Zha Z.G., Zhou C.R. Preparation, structure and drug release behaviour of chitosan-based nanofibres. IET Nanobiotechnol 2009, 3:8-13.
19. Misra R., Sahoo S.K. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 2010, 39:152-163.
20. Jain T.K., Richey J., Strand M., Leslie-Pelecky D.L., Flask C.A., Labhasetwar V. Magnetic nanoparticles with dual functional properties: Drug delivery and magnetic resonance imaging. Biomaterials 2008, 29:4012-4021.
21. Mohanty C., Acharya S., Mohanty A.K., Dilnawaz F., Sahoo S.K. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: A novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond) 2010, 5:433-449.
22. Xiao Z., Xue J., Sowin T.J., Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006, 5:1935-1943.
23. Parsels L.A., Morgan M.A., Tanska D.M., Parsels J.D., Palmer B.D., Booth R.J., et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009, 8:45-54.
24. Xu Y., Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 2003, 250:215-226.
25. Tseng C.L., Su W.Y., Yen K.C., Yang K.C., Lin F.H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
26. Mohanty C., Sahoo S.K. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010, 31:6597-6611.
27. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59:748-758.
28. Davda J., Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 2002, 233:51-59.
29. Lee A.L., Wang Y., Cheng H.Y., Pervaiz S., Yang Y.Y. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 2009, 30:919-927.
30. Konishi A., Shimizu S., Hirota J., Takao T., Fan Y., Matsuoka Y., et al. Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks. Cell 2003, 114:673-688.
31. Robinson K., Lambiase L., Li J., Monteiro C., Schiff M. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 2003, 48:1804-1808.
32. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997; 24:S7-2-S7-
33. Sahoo S.K., Parveen S., Panda J.J. The present and future of nanotechnology in human health care. Nanomedicine 2007, 3:20-31.
34. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000, 65:271-284.
35. Maraldo D., Mutharasan R. Optimization of antibody immobilization for sensing using piezoelectrically excited-millimeter-sized cantilever (PEMC) sensors. Sens Actuators B 2007, 123:474-479.
36. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995, 22:3-10.
37. Huang P., Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 1995, 22:19-25.
38. Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996, 23:3-15.
39. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868.
40. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 1993, 53:3976-3985.
41. Ewald B., Sampath D., Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007, 6:1239-1248.